<DOC>
	<DOCNO>NCT01940965</DOCNO>
	<brief_summary>Primary Objective : The primary objective study ass overall safety lixisenatide daily treatment combination background oral anti-diabetic treatment 52 week patient type 2 diabetes Japan . Secondary Objective : To assess effect lixisenatide combination background oral antidiabetic drug ( OAD ) : - HbA1c ; - Fasting plasma glucose ; - Body weight .</brief_summary>
	<brief_title>Safety Tolerability Lixisenatide Combination With Oral Anti-Diabetic Treatment Patients With Type 2 Diabetes</brief_title>
	<detailed_description>54 week +/-11 day</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Inclusion criterion : Patients type 2 diabetes mellitus diagnose least 1 year screen visit Patient treat least 3 month prior screen visit one follow OADs stable dose least usual maintenance dose describe label biguanide ( metformin hydrochloride ) ; thiazolidinedione ( TZD ) ( pioglitazone hydrochloride ) ; alphaglucosidase inhibitor ( alphaGI ) ( acarbose , voglibose miglitol ) ; glinide ( nateglinide , repaglinide mitiglinide ) ; Signed write informed consent Exclusion criterion : At screen HbA1c &lt; 7 % &gt; 9.5 % ; At screening : fasting plasma glucose &gt; 250 mg/dL ( &gt; 13.9 mmol/L ) ; Use glucoselowering agent ( ) authorize patient 's background treatment define I02 ( give inclusion critieria ) within 3 month prior screen ; Type 1 diabetes mellitus ; Women childbearing potential effective contraceptive method ; Pregnancy lactation ; Laboratory finding time screening : Amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) ; ALT &gt; 3 ULN ; Any contraindication patient 's background oral antidiabetic treatment ; History acute chronic pancreatitis , pancreatectomy , stomach/gastric surgery , inflammatory bowel disease ; Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( eg , multiple endocrine neoplasia syndrome ) ; Any previous treatment lixisenatide ( eg , participation previous study lixisenatide ) GLP1 receptor agonist . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>